Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy tailors radiation for advanced nasopharyngeal cancer

NCT ID NCT07248696

Disease control Sponsor: Chongqing University Cancer Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase II trial tests a personalized treatment for metastatic nasopharyngeal carcinoma. Patients first receive tislelizumab (immunotherapy) plus chemotherapy. Those who respond well may avoid or reduce radiotherapy, while others get targeted radiation. The study aims to see if this approach improves progression-free survival with fewer side effects. It involves 32 participants and is active but not recruiting.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Tislelizumab (an immunotherapy drug) combined with gemcitabine and cisplatin chemotherapy, plus radiotherapy adjusted based on tumor response
What this could lead to
If successful, this approach could offer a more personalized treatment for metastatic nasopharyngeal carcinoma, potentially reducing the need for radiotherapy in patients who respond well to initial therapy.
What could go wrong
This is a small, early-phase trial with only 32 participants, so results may not apply to everyone. The combination therapy also carries risks of side effects from chemotherapy, immunotherapy, and radiation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 32 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Jun 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 18-70 years. 2. Newly diagnosed nasopharyngeal carcinoma with pathological confirmation of non-keratinizing carcinoma (WHO type II or III). 3. Stage IV (T1-4N0-3M1a and M1b) according to the AJCC/UICC 9th edition clinical staging system for NPC. 4. Achieved complete response (CR) or partial response (PR) by imaging evaluation after 4-6 cycles of GP chemotherapy combined with tislelizumab. 5. ECOG performance status: 0-1. 6. Adequate organ function. Exclusion Criteria: 1. Recurrent or metastatic nasopharyngeal carcinoma after radical treatment. 2. Other malignancies diagnosed or treated within the past 5 years (except basal cell carcinoma, cervical carcinoma in situ, and superficial bladder tumors). 3. Previous treatment with immune checkpoint inhibitors. 4. Pregnancy or lactation (consider pregnancy testing for women of childbearing age and emphasize effective contraception during treatment). 5. Active or history of autoimmune diseases. 6. Concurrent medical condition requiring the use of immunosuppressive medications. 7. Active hepatitis B or C infection.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Nasopharyngeal cancinoma (NPC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

nasopharyngeal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Nasopharyngeal cancinoma (NPC)

Contacts and locations

Locations

  • Chongqing University Cancer Hospital

    Chongqing, Chongqing Municipality, 400000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.